Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
15 03 2019
Historique:
received: 22 01 2019
accepted: 28 02 2019
revised: 22 02 2019
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 16 5 2020
Statut: epublish

Résumé

Under physiological conditions, a finely tuned system of cellular adaptation allows the intestinal mucosa to maintain the gut barrier function while avoiding excessive immune responses to non-self-antigens from dietary origin or from commensal microbes. This homeostatic function is compromised in cystic fibrosis (CF) due to loss-of-function mutations in the CF transmembrane conductance regulator (CFTR). Recently, we reported that mice bearing defective CFTR are abnormally susceptible to a celiac disease-like enteropathy, in thus far that oral challenge with the gluten derivative gliadin elicits an inflammatory response. However, the mechanisms through which CFTR malfunction drives such an exaggerated response to dietary protein remains elusive. Here we demonstrate that the proteostasis regulator/transglutaminase 2 (TGM2) inhibitor cysteamine restores reduced Beclin 1 (BECN1) protein levels in mice bearing cysteamine-rescuable F508del-CFTR mutant, either in homozygosis or in compound heterozygosis with a null allele, but not in knock-out CFTR mice. When cysteamine restored BECN1 expression, autophagy was increased and gliadin-induced inflammation was reduced. The beneficial effects of cysteamine on F508del-CFTR mice were lost when these mice were backcrossed into a Becn1 haploinsufficient/autophagy-deficient background. Conversely, the transfection-enforced expression of BECN1 in human intestinal epithelial Caco-2 cells mitigated the pro-inflammatory cellular stress response elicited by the gliadin-derived P31-43 peptide. In conclusion, our data provide the proof-of-concept that autophagy stimulation may mitigate the intestinal malfunction of CF patients.

Identifiants

pubmed: 30874543
doi: 10.1038/s41419-019-1500-x
pii: 10.1038/s41419-019-1500-x
pmc: PMC6420598
doi:

Substances chimiques

Beclin-1 0
Becn1 protein, mouse 0
Cftr protein, mouse 0
Cytokines 0
Peptide Fragments 0
TGM2 protein, human 0
gliadin p31-43 0
Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6
Cysteamine 5UX2SD1KE2
Gliadin 9007-90-3
Protein Glutamine gamma Glutamyltransferase 2 EC 2.3.2.13
Transglutaminases EC 2.3.2.13
GTP-Binding Proteins EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

258

Références

Cell Rep. 2018 Feb 27;22(9):2395-2407
pubmed: 29490275
Cell Physiol Biochem. 2011;28(1):115-24
pubmed: 21865854
J Immunol. 2009 Aug 15;183(4):2775-84
pubmed: 19625650
Nature. 2011 Mar 10;471(7337):220-4
pubmed: 21307853
Acta Biochim Pol. 2010;57(1):115-8
pubmed: 20300660
J Immunol. 2008 Jun 1;180(11):7697-705
pubmed: 18490773
Pediatr Res. 2000 Mar;47(3):344-50
pubmed: 10709733
Int J Mol Sci. 2014 Nov 07;15(11):20518-37
pubmed: 25387079
Nat Rev Immunol. 2015 Dec;15(12):771-83
pubmed: 26567920
Cell Death Differ. 2013 Aug;20(8):1101-15
pubmed: 23686137
Science. 1989 Sep 8;245(4922):1066-73
pubmed: 2475911
Cell. 2019 Jan 10;176(1-2):11-42
pubmed: 30633901
Mol Cell. 2010 Oct 22;40(2):280-93
pubmed: 20965422
Cell Death Dis. 2017 Jan 12;8(1):e2544
pubmed: 28079883
J Clin Invest. 2016 Mar 1;126(3):879-91
pubmed: 26808501
Cell Death Differ. 2017 Nov;24(11):1825-1844
pubmed: 28937684
Front Pharmacol. 2013 Jan 21;4:1
pubmed: 23346057
BMJ. 2016 Mar 30;352:i859
pubmed: 27030675
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5382-7
pubmed: 27114540
Gastroenterology. 2015 Sep;149(3):681-91.e10
pubmed: 26001928
Cell Death Differ. 2015 Mar;22(3):509-16
pubmed: 25526088
Nat Genet. 2013 Oct;45(10):1160-7
pubmed: 23974870
Acta Paediatr. 1994 Apr;83(4):440-1
pubmed: 8025407
Lancet. 2003 Feb 22;361(9358):681-9
pubmed: 12606185
Cold Spring Harb Perspect Med. 2013 Sep 01;3(9):a009753
pubmed: 23788646
EMBO J. 2019 Jan 15;38(2):
pubmed: 30498130
EMBO J. 2007 May 16;26(10):2527-39
pubmed: 17446862
Sci Transl Med. 2015 Feb 25;7(276):276ra27
pubmed: 25717100
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Annu Rev Biochem. 2015;84:435-64
pubmed: 25784053
Immunity. 2012 Jun 29;36(6):907-19
pubmed: 22749351
Nat Rev Immunol. 2013 Apr;13(4):294-302
pubmed: 23493116
Nat Rev Genet. 2015 Jan;16(1):45-56
pubmed: 25404111
Annu Rev Genomics Hum Genet. 2016 Aug 31;17:155-75
pubmed: 26905785
Front Pharmacol. 2016 Sep 05;7:275
pubmed: 27656143
Lancet. 2009 May 30;373(9678):1891-904
pubmed: 19403164
N Engl J Med. 2015 Jan 22;372(4):351-62
pubmed: 25607428
Lancet. 2003 Jul 5;362(9377):30-7
pubmed: 12853196
Cell Death Differ. 2016 Aug;23(8):1380-93
pubmed: 27035618
Mucosal Immunol. 2009 Jan;2(1):8-23
pubmed: 19079330
Lancet Respir Med. 2016 Aug;4(8):662-674
pubmed: 27053340
Nat Rev Drug Discov. 2017 Jul;16(7):487-511
pubmed: 28529316
Autophagy. 2014;10(11):2053-74
pubmed: 25350163
Cell Cycle. 2017 Feb;16(3):271-279
pubmed: 28059601
EMBO Rep. 2018 Jul;19(7):
pubmed: 29752334
J Cyst Fibros. 2009 May;8(3):198-202
pubmed: 19303374
Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S39-56
pubmed: 26335954
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):175-85
pubmed: 26790364
Nat Med. 2017 May;23(5):590-600
pubmed: 28394330
Nature. 2006 Mar 23;440(7083):477-83
pubmed: 16554808
Nat Cell Biol. 2010 Sep;12(9):863-75
pubmed: 20711182
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):491-2
pubmed: 26194946
Pediatr Res. 2012 May;71(5):532-8
pubmed: 22314661
Pediatr Pulmonol. 2013 Aug;48(8):761-71
pubmed: 22825912
J Cyst Fibros. 2014 Jul;13(4):403-9
pubmed: 24440181

Auteurs

Valeria R Villella (VR)

European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy.

Speranza Esposito (S)

European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy.

Eleonora Ferrari (E)

European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy.
Department of Health Sciences, University of Eastern Piedmont, Novara, 28100, Italy.

Romina Monzani (R)

European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy.
Department of Health Sciences, University of Eastern Piedmont, Novara, 28100, Italy.

Antonella Tosco (A)

Regional Cystic Fibrosis Center, Pediatric Unit, Department of Translational Medical Sciences, Federico II University Naples, Naples, 80131, Italy.

Federica Rossin (F)

Department of Biology, University of Rome "Tor Vergata", Rome, Italy.

Alice Castaldo (A)

Regional Cystic Fibrosis Center, Pediatric Unit, Department of Translational Medical Sciences, Federico II University Naples, Naples, 80131, Italy.

Marco Silano (M)

Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Roma, Italy.

Gian Luigi Marseglia (GL)

Dipartimento di Pediatria, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Luigina Romani (L)

Department of Experimental Medicine, University of Perugia, Perugia, Italy.

Nikolai A Barlev (NA)

Gene Expression Laboratory, Institute of Citology, Saint-Petersburg, Russia.

Mauro Piacentini (M)

Department of Biology, University of Rome "Tor Vergata", Rome, Italy.

Valeria Raia (V)

Regional Cystic Fibrosis Center, Pediatric Unit, Department of Translational Medical Sciences, Federico II University Naples, Naples, 80131, Italy.

Guido Kroemer (G)

Equipe11 labellisée Ligue Nationale contrele Cancer, Centre de Recherche des Cordeliers, Paris, France. kroemer@orange.fr.
INSERM U1138, Centre de Recherche des Cordeliers, Paris, France. kroemer@orange.fr.
Université Paris Descartes, Paris, France. kroemer@orange.fr.
Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France. kroemer@orange.fr.
Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. kroemer@orange.fr.
Suzhou Institute for Systems Biology, Chinese Academy of Sciences, Suzhou, China. kroemer@orange.fr.
Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, 17176, Sweden. kroemer@orange.fr.

Luigi Maiuri (L)

European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy.
Department of Health Sciences, University of Eastern Piedmont, Novara, 28100, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH